Is Australia ready to use glycated haemoglobin for the diagnosis of diabetes?

HbA1c may be a practical alternative to blood glucose for the diagnosis of diabetes

For more than 15 years, glycated haemoglobin (HbA1c) has been recommended as the key tool for assessing glycaemic control in people with diabetes. Only in 2009 did the first advice to use HbA1c levels for diabetes diagnosis appear, using a cut-point of ≥ 6.5%.1 To date, no clear argument has been articulated to explain why HbA1c levels have been deemed superior to laboratory-determined blood glucose levels for determining the need for insulin therapy, but not for diagnosing diabetes; however, it is likely that implications of the former are greater than those of the latter, for both individuals and society.